#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2022 - 1

Tobacco dependence treatment guidelines

Czech version

Authors: Eva Králíková 1,2,3;  Kamila Zvolská 1,3;  Lenka Štěpánková 1,3;  Alexandra Pánková 1,2,3
Authors‘ workplace: Centrum pro závislé na tabáku, 3. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze 1;  Ústav hygieny a epidemiologie 1. LF UK a VFN v Praze 2;  Společnost pro léčbu závislosti na tabáku, z. s. 3
Published in: Čas. Lék. čes. 2022; 161: 33-43
Category: Guidelines

Overview

These recommendations are relevant for all clinical fields and all medical professions, although for some more and for some less. Smoking is the cause of every sixth death in the Czech Republic and is related to diseases of all organ systems. Effective treatment for the diagnosis of F17 exists and should be offered and available to approximately 2 million smokers in the Czech Republic as a standard part of medical and preventive care according to time availability – from brief intervention in frame of each clinical contact with the patient to intensive care. It includes psycho-socio-behavioral support and pharmacotherapy. It should cover all professions in clinical medicine – according to WHO recommendations, especially doctors, nurses, pharmacists and dentists and should be reimbursed within health systems. It should also be offered in other services like e.g., social or addictology care. From an economic point of view, it is one of the most cost-effective interventions in medicine.

Keywords:

Physicians – Nurses – Pharmacists – treatment – tobacco dependence – practice guideline – medical specialities

Sources
  1. Peto R, Lopez AD, Pan H et al. Mortality from smoking in developed countries 1950-2020. Updated September 2015. Oxford University Press, 2020. Dostupné na: www.ctsu.ox.ac.uk/~tobacco
  2. Csémy L, Dvořáková Z, Fialová A a kol. Národní výzkum užívání tabáku a alkoholu v České republice 2020 (NAUTA). Státní zdravotní ústav, Praha, 2021. Dostupné na: www.szu.cz/uploads/documents/szu/aktual/nauta_2020.pdf
  3. Eurobarometer 506. Attitudes of Europeans towards tobacco and electronic cigarettes. European Commission, Brusel, 2021. Dostupné na: https://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/survey/getsurveydetail/instruments/special/surveyky/2240
  4. World Health Organization. Guidelines for implementation of Article 14 of the WHO Framework Convention on Tobacco Control (Demand reduction measures concerning tobacco dependence and cessation). WHO, 2010. Dostupné na: www.who.int/fctc/guidelines/adopted/article_14/en
  5. Mezinárodní smlouva č. 71/2012 Sb. Sdělení Ministerstva zahraničních věcí o sjednání Rámcové úmluvy Světové zdravotnické organizace o kontrole tabáku. Dostupné na: www.zakonyprolidi.cz/ms/2012-71
  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. APA, Washington, DC, 2013. Dostupné na: www.psychiatry.org/practice/dsm
  7. Rolle-Lake L, Robbins E. Behavioral risk factor surveillance system. StatPearls Publishing, Treasure Island, 2022.
  8. Hughes JR. Minnesota Tobacco Withdrawal Scale-Revised. Dostupné na: www.med.uvm.edu/docs/behavior_rating_scale_self/behavior-and-health-documents/behavior_rating_scale_self.pdf?sfvrsn=372e8344_2
  9. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerström test for cigarette dependence. Nicotine Tob Res 2012; 14(1): 75–78.
  10. West R, Hajek P, Stead L et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100(3): 299–303.
  11. Fiore MC, Jaén CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. US Department of Health and Human Services, Rockville, 2008. Dostupné na: www.ncbi.nlm.nih.gov/books/NBK63952
  12. Brown J, Beard E, Kotz D et al. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. Addiction 2014; 109(9): 1531–1540.
  13. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329.
  14. Hartmann-Boyce J, Stead LF, Cahill K et al. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction 2014; 109(9): 1414–1425.
  15. Králíková E, Kmeťová A, Štěpánková L et al. Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. Addiction 2013; 108(8): 1497–1502.
  16. Royal Australian College of General Practitioners. Supporting Smoking Cessation. A Guide for Health Professionals, revision 2020. RACGP, 2020.
  17. The New Zealand Guidelines to Help People to Stop Smoking, update 2021. Ministry of Health, Wellington, 2021. Dostupné na: www.health.govt.nz/publication/new-zealand-guidelines-helping-people-stop-smoking-update
  18. National Institute for Health and Care Excellence. Stop smoking interventions and services. NICE guideline [NG92]. NICE, 28. 3. 2018. Dostupné na: www.nice.org.uk/guidance/ng92
  19. The National Centre for Smoking Cessation and Training. Dostupné na: www.ncsct.co.uk
  20. Association for the Treatment and of Tobacco Use and Dependence. Dostupné na: www.attud.org
  21. Action on Smoking and Health. Dostupné na: https://ash.org/programs/resources  
  22. Smoking Cessation Leadership Centre. Dostupné na: https://smokingcessationleadership.ucsf.edu
  23. Hurt RD, Ebbert JO, Hays JT, McFadden DD. Treating tobacco dependence in a medical setting. CA Cancer J Clin 2009;59(5): 314–326.
  24. Králíková E, Češka R, Pánková A a kol. Doporučení pro léčbu závislosti na tabáku. Vnitřní lékařství 2015; 61(Suppl. 1): 1S4–1S15.
  25. Zvolská K, Králíková E. Centra pro závislé na tabáku v ČR v roce 2016. Časopis lékařů českých 2017; 156(1): 19–23.
  26. Centre of Excellence for Health Systems Improvement. Documenting, coding & billing for tobacco dependence treatment. A guide to maximizing reimbursement. HSI, 2018. Dostupné na: www.tobaccofreeny.org/images/hsi/Resources/Documenting-Coding-Billing-For-Tobacco-Dependence-Treatment.pdf
  27. Chaiton M, Diemert L, Cohen JE et al. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open 2016; 6(6): e011045.
  28. World Health Organization. Two new tobacco cessation medicines added to the WHO essential medicines list, WHO, 5. 11. 2021. Dostupné na: www.who.int/news/item/05-11-2021-two-new-tobacco-cessation-medicines-added-to-the-who-essential-medicines-list
  29. Benowitz NL, Pipe A, West R et al. cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med 2018; 178(5): 622–631.
  30. Anthenelli RM, Benowitz NL, West R et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387(10037): 2507–2520.
  31. Kotz D, Brown J, West R et al. Real-world effectiveness of smoking cessation treatments: a population study. Addiction 2014; 109: 491–499.
  32. Kotz D, Brown J, West R et al. Prospective cohort study of the effectiveness of smoking cessation treatments used in the "real world". Mayo Clinic Proc 2014; 89(10): 1360–1367.
  33. Jackson SE et al. Moderators of real-world effectiveness of smoking cessation aids: a population study. Addiction 2019; 114(9): 1627–1638.
  34. Hajat C, Polosa R, Selya A, Stein E. Critical analysis of common methodology flaws in e-cigarette surveys. Qeios, 2021. Dostupné na: www.qeios.com/read/IZGWNJ.4
  35. Obertová N, Navrátil T, Žák I, Zakharov S. Acute exposures to e-cigarettes and heat-not-burn products reported to the Czech Toxicological Information Centre over a 7-year period (2012-2018). Basic Clin Pharmacol Toxicol 2020; 127(1): 39–46.
  36. Benowitz NL, St Helen G, Liakoni E. Clinical pharmacology of electronic nicotine delivery systems (ENDS): Implications for benefits and risks in the promotion of the combusted tobacco endgame. J Clin Pharmacol 2021; 61 (Suppl 2.): S18–S36.
  37. Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR et al. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev 2016; 10: CD005231.
  38. Balfour DJK, Benowitz NL, Colby SM et al. Balancing consideration of the risks and benefits of e-cigarettes. Am J Public Health 2021; 111(9): 1661–1672.
  39. Hartmann-Boyce J, McRobbie H, Butler AR et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2021; 9(9): CD010216.
  40. Bates C. The outbreak of lung injuries often known as "EVALI" was nothing to do with nicotine vaping. Qeios, 2021. Dostupné na: www.qeios.com/read/ZGVHM7.2
  41. Králíková E. E-detektivka: klasické e-cigarety to nebyly. Hygiena 2020; 65(1): 27–28.
  42. St Helen G, Jacob Iii P, Nardone N, Benowitz NL. IQOS: examination of Philip Morris International's claim of reduced exposure. Tob Control 2018; 27(Suppl. 1): s30–s36.
  43. Šídová M, Šťastná L. Kouření v těhotenství. Adiktologie 2015; 15(2): 164–172.
  44. Wilhelmová R, Greiffeneggová L. Selected indicators related to smoking incidence in pregnant women in the Czech Republic. Kontakt 2019; 21(2): 181–188.
  45. Scheffers-van Schayck T, Tuithof M et al. smoking behavior of women before, during, and after pregnancy: indicators of smoking, quitting, and relapse. Eur Addict Res 2019; 25(3): 132–144.
  46. Bancej C, O'Loughlin J, Platt RW et al. Smoking cessation attempts among adolescent smokers: a systematic review of prevalence studies. Tob Control 2007; 16(6): e8.
  47. Shields, PG, Herbst, ES, Davis J et al. NCCN Clinical Practice Guidelines in Oncology: Smoking Cessation. Version 1.2015. NCCN, 2015
  48. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290(1): 86–97.
  49. Twardella D, Küpper-Nybelen J, Rothenbacher D et al. Short-term benefit of smoking cessation in patients with coronary heart disease: estimates based on self-reported smoking data and serum cotinine measurements. Eur Heart J 2004; 25(23): 2101–2108.
  50. Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019; 26(8): 824–835.
  51. Barua RS, Rigotti NA, Benowitz NL et al. ACC expert consensus decision pathway on tobacco cessation treatment: a report of The American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2018; 72(25): 3332–3365.
  52. Zvolská K, Králíková E, Škrha J. Kouření a diabetes mellitus. DMEV 2018; 21: 9–14.
  53. Jones SE, Mulrine S, Clements H, Hamilton S. Supporting mental health service users to stop smoking: findings from a process evaluation of the implementation of smoke-free policies into two mental health trusts. BMC Public Health 2020; 20(1): 1619.
  54. Petr T, Kasal M. Zkušenosti se zaváděním nekuřácké politiky na oddělení psychiatrické péče v ÚVN. Česká a slovenská psychiatrie 2020; 116 (4): s177–182.
  55. Kulhánek A, Mašlaniová M. Pilotní spuštění nekuřáckého detoxifikačního oddělení Kliniky adiktologie 1. LF UK a VFN v Praze. Adiktologie v preventivní a léčebné praxi 2020; 3(2): 106–111.
  56. Hunt JJ, Cupertino AP, Garrett S et al. How is tobacco treatment provided during drug treatment? J Subst Abuse Treat 2012; 42(1): 4–15.
  57.  Hunt JJ, Cupertino AP, Gajewski BJ et al. Staff commitment to providing tobacco dependence in drug treatment: Reliability, validity, and results of a national survey, Psychol Addict Behav 2014; 28(2): 389–395
  58. Zaki A, Abrishami A, Wong J, Chung FF. Interventions in the preoperative clinic for long term smoking cessation: a quantitative systematic review. Can J Anaesth 2008; 55(1): 11–21.
  59. World Bank. Curbing the epidemic: governments and the economics of tobacco control. World Bank, Washington, DC, 1999.
  60. Králíková E, Kmeťová A, Felbrová V et al. Centra pro závislé na tabáku v České republice v roce 2012: přehled, ekonomika. Časopis lékařů českých 2014; 153(5): 246–250.
  61. Mahmoudi M, Coleman CI, Sobieraj DM. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation. Int J Clin Pract 2012; 66(2): 171–182.
  62. Reisinger SA, Kamel S, Seiber E et al. Cost-effectiveness of community-based tobacco dependence treatment interventions: initial findings of a systematic review. Prev Chronic Dis 2019; 16: E161.
  63. Croghan IT, Offord KP, Evans RW et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc 1997; 72(10): 917–924.
  64. Flack S, Taylor M, Trueman P et al. NICE. Cost-effectiveness of interventions for smoking cessations. York Health Economics Consortium 2007. Final report. NICE and The University of York, 2007.
  65. Cromwell J, Bartosch WJ, Fiore MC et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR Guideline for Smoking Cessation. JAMA 1997; 278(21): 1759–1766.
  66. Goodchild M, Nargis N, Tursan d'Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control 2018; 27(1): 58–64.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Current treatment options for monogenic periodic fever syndromes – the role of interleukin 1 inhibitors
Physiology of ageing
Do clinical pharmacists contribute to fall prevention in healthcare facilities also in the Czech Republic? 10 years of monitoring and experience from ÚVN Prague
Multi-branch cooperation on SARS-CoV-2 omicron capture: a case report
Domácí transfuze v kontextu poskytování paliativní péče v Česku
17. Šonkův den
Ohlédnutí za konferencí IZS Karlovy Vary 2021
Odešel nestor české geriatrie docent Jiří Neuwirth
PŘEDNÁŠKOVÉ VEČERY SPOLKU ČESKÝCH LÉKAŘŮ V PRAZE (DUBEN – ČERVEN 2022)
Article was published in

Journal of Czech Physicians

Issue 1
2022 Issue 1
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#